Introduction
The antiphospholipid syndrome (APS) is an autoimmune condition associated with thrombosis (venous or arterial) and adverse pregnancy outcomes. Investigation of APS began with the discovery of autoantibodies in patients with syphilis in 1906, characterization of biologic false-positive results of serologic tests for syphilis due to reactivity with anticardiolipin antibodies (aCL) in 1952, and followed soon after by the identification of "circulating anticoagulants" in women with adverse pregnancy outcomes. In the 1980s, the association of thrombosis, miscarriages, and lupus anticoagulant (LAC) was discovered, and the term "antiphospholipid syndrome" was coined.
The diagnosis of APS is based on the clinical obstetric and/or thrombosis history and laboratory findings of persistently positive (on 2 occasions at least 12 weeks apart) antiphospholipid antibodies (aPL) ( Table 1) .
Antiphospholipid antibodies are a heterogeneous group of autoantibodies directed against a complex antigen consisting of negatively charged phospholipids and phospholipid binding proteins. The best recognized of these, and the aPL required to make a diagnosis of APS, are LAC, aCL, and anti-b 2 -glycoprotein I (anti-b 2 GPI) antibodies (1) . The performance characteristics of aPL immunoassays for aCL and anti-b 2 GPI and the widely recognized interlaboratory variability in the results of aPL immunoassays demand that reliable laboratories identify medium-or high-titer results (Table 1) . Furthermore, the specificity of aCL and antib 2 GPI antibodies for APS increases with higher titers and with the IgG isotype. The requirement for repeatedly positive results exists because other conditions can result in transiently positive aPL results. The presence of LAC, and in some series anti-b 2 GPI antibodies, is a better predictor of pregnancy morbidity than are aCL (2, 3) . "Triple" aPL positivity (LAC, aCL, and anti-b 2 GPI) is of greater clinical significance than double or single aPL positivity (4) .
Antiphospholipid antibodies are detectable in up to 5% of asymptomatic individuals. They are more common in patients with systemic autoimmune disease, particularly systemic lupus erythematosus (SLE). The frequency of aPL in patients with SLE is ;30% (5) . The association of aPL with recurrent miscarriage (pregnancy loss at ,10 weeks of gestation) is variable and has recently been challenged because of flaws in historic studies, including poor standardization of assays, variability in the definitions of aPL positivity, and inclusion of women with other causes of recurrent miscarriage (6) . Moreover, recent studies have shown no increase in the frequency of high aPL levels in women with recurrent pregnancy losses at ,10 weeks of gestation (7) .
Pregnancy complications remain a frequent and challenging problem in patients with APS. The primary treatment for pregnant women with APS is focused on preventing thrombosis but is only partially successful. At present, .80% of pregnancies result in a live birth. However, these pregnancies are at increased risk of preeclampsia (particularly early, severe preeclampsia) in 18-40% of pregnancies, intrauterine growth restriction (IUGR) in 5-15% of pregnancies, and preterm delivery, despite treatment with drugs such as heparin and lowdose aspirin (8) .
Given that the salient extraplacental manifestations of APS are vascular thromboses, and that thrombi are present occasionally, anticoagulation has been used to prevent pregnancy morbidity. Experimental models have emphasized the role of inflammation rather than thrombosis, and histopathologic findings in the placentas of women with APS support the notion that proinflammatory factors, rather than thrombosis, contribute to injury (9, 10) . Although it is clear that the specific antigenic reactivity of aPL and their targeting to the placenta are critical to their effect, pathogenic mechanisms that damage the fetal-maternal unit and cause abnormal placental development are incompletely understood. Indeed, the in vivo antigenic targets of LAC, the strongest risk factor for adverse pregnancy outcomes in APS patients, are not known. The heterogeneity of aPL may lead to the initiation of different pathways of injury. It is not known to what extent impaired fetal growth or fetal demise depends on aPL-initiated inflammation, aPL- triggered modulation of trophoblast or endothelial cell function, or aPL-mediated thrombosis. In this review, we describe the pathogenic mechanisms of pregnancy complications in APS and approaches that can be brought to the clinic to prevent adverse pregnancy outcomes.
Normal placental development
The human placenta is covered by a single multinucleated cell, the syncytiotrophoblast. Shortly after implantation, mononuclear trophoblasts (cytotrophoblasts) invade from the placenta into the uterine decidua, differentiating into extravillous trophoblasts. Some extravillous trophoblasts then invade the uterine spiral arteries, which supply blood to the decidua by digesting the muscular walls and replacing the endothelial cells that line these vessels. This invasion remodels the spiral arteries into nonvasoactive large bore conduits (11) . By midgestation, the spiral arteries are remodeled through the depth of the decidua and one-third of the depth of their myometrial segments ( Figure 1C ). This remodeling allows the large and uninterrupted blood supply that is required during the second half of pregnancy when fetal demand is greatest. However, during the initial invasion of the spiral arteries, trophoblasts form loosely cohesive plugs in the lumen of the spiral arteries ( Figure 1B) (12) . These plugs temporarily block the passage of maternal red blood cells, allowing early placental development to occur in the absence of oxidative stress, but the plugs have channels that allow the movement of plasma to the placenta (13) . Therefore, aPL can access the syncytiotrophoblast and extravillous trophoblasts throughout the course of gestation ( Figures  1 and 2 ). A, Nonpregnant uterus, in which tightly coiled spiral arteries with musculoelastic walls connect, via capillary beds, to the decidual veins. B, Pregnant uterus in the first trimester, in which extravillous trophoblasts (EVTs) invade from the placenta into the spiral arteries and start to remodel the vessels, removing the musculoelastic walls. At this early stage, the invasive trophoblasts (TB) form loosely cohesive plugs that occlude maternal red blood cells but permit the passage of plasma, allowing antiphospholipid antibodies to access the syncytiotrophoblast (STB) and invading cytotrophoblasts. C, Pregnant uterus at midgestation in a normal pregnancy, in which the spiral arteries (30-50 affected) are remodeled by invading trophoblasts to one-third of the depth of the myometrium. D, Pregnant uterus at midgestation, in which spiral arteries are only partially remodeled and remain tonically active, reducing blood flow to the placenta, leading to preeclampsia (PE) and/or small for gestational age (SGA) fetuses/newborns. E, Pregnant uterus at midgestation, in which remodeling of the spiral arteries is very limited, with severely reduced volume and increased velocity of blood flow to the placenta, leading to severe placental damage, PE, SGA, and/or stillbirth.
Abnormal placental development in APS
The major obstetric manifestations of APS, including preeclampsia, IUGR, and stillbirths, are characterized by a failure of extravillous trophoblasts to adequately remodel the spiral arteries ( Figure 2 ). The consequence is reduced/interrupted maternal blood flow to the placenta, with hypoxic/ischemic injury, inadequate delivery of nutrients to the fetus, and/or high-velocity blood flow that may damage the placenta (13) . Antiphospholipid antibodies can reduce the proliferation and invasion of extravillous trophoblasts both in vitro and in vivo. The inability of trophoblasts to remodel spiral arteries is clinically silent (14) , but the resultant placental malperfusion may drive production of the potent antiangiogenic factors soluble Flt-1 (also known as soluble vascular endothelial growth factor [VEGF]) and soluble endoglin. Soluble Flt-1 sequesters the proangiogenic factors VEGF and placental growth factor, preventing their binding to trophoblast and VEGF receptors and antagonizing their proangiogenic actions (15) (16) (17) . In the maternal circulation, excess soluble Flt-1 produces a deficiency of angiogenic factors required for endothelial vascular homeostasis (15) , leading to clinical manifestations of preeclampsia (18) (19) (20) (21) .
A recent meta-analysis of the histopathologic findings in controlled studies of placentae from aPLaffected pregnancies revealed the following 5 features that are associated with aPL: 1) placental infarction, 2) impaired spiral artery remodeling, 3) decidual inflammation, 4) increased syncytial knots, and 5) decreased vasculosyncytial membranes (10) . Of note, the placentae of women with aPL rarely show evidence of intravascular or intervillous blood clots (10) . In the following sections, we will describe the pathologic mechanisms for these findings.
Mediators and mechanisms of aPL-induced abnormal placental development
Antiphospholipid antibody interactions with trophoblasts. Antiphospholipid antibodies recognizing b 2 GPI have been shown to be pathologic in obstetric APS, in part because the antigen is constitutively expressed at the cell surface by all placental trophoblast subpopulations (22) . Beta 2 -glycoprotein I is also present on maternal decidual endothelial cells. Beta 2 -glycoprotein I binds human trophoblasts and endothelium through the phospholipid binding site in domain V of the molecule, as well as via various receptors ( Figures 3A and B) . Thus, the placenta is a major target for b 2 GPI-dependent pathogenic aPL binding, and subsequently, aPL alter trophoblast function. Although the outer placental syncytiotrophoblast and invading extravillous trophoblast populations both bind anti-b 2 GPI antibodies, the syncytiotrophoblast internalizes aPL via a low-density lipoprotein receptor (LDLR) family member ( Figure  3D ), while the extravillous trophoblast maintains aPL on the cell surface (23, 24 ). As will be described below, this results in distinct responses by the trophoblast subpopulations to aPL.
Impact of aPL on extravillous trophoblast function. Because adverse pregnancy outcomes are established early in gestation, and women with APS have circulating aPL prior to embryo implantation, it is important to understand the impact that these autoantibodies have on early placentation. Studies using human first-trimester extravillous trophoblasts have shown that aPL induce changes similar to those in preeclampsia. These in vitro studies demonstrated that aPL recognizing b 2 GPI trigger human first-trimester extravillous trophoblasts to produce elevated levels of proinflammatory cytokines and chemokines, inhibit spontaneous trophoblast migration, increase trophoblast antiangiogenic soluble endoglin secretion ( Figures 3A and B) , and disrupt trophoblastendothelial interactions in a model of spiral artery transformation (25) (26) (27) (28) .
Antiphospholipid antibody-induced trophoblast inflammation. Antiphospholipid antibodies induce trophoblasts to secrete inflammatory interleukin-1b (IL1b) and IL-8 via activation of Toll-like receptor 4 (TLR-4) and its adapter protein myeloid differentiation factor 88 (MyD88) (Figure 3B ), most likely because b 2 GPI shares molecular mimicry with lipopolysaccharide (25) . Downstream of MyD88, IL-1b secretion is mediated by induction of the danger signal, uric acid, which in turn activates the NLRP3 inflammasome to process IL-1b (29) . In parallel, IL-8 production downstream of TLR-4 is mediated by induction of microRNA-146a-3p (miR146a-3p), which directly activates the RNA sensor TLR-8 (30) . Thus, aPL-induced miR-146a-3p and uric acid act as endogenous secondary signals for activation of TLR-8 and the NLRP3 inflammasome in trophoblasts, to drive trophoblast inflammation.
Reduced trophoblast migration and invasion caused by aPL. Reduced trophoblast migration caused by aPL is mediated by apolipoprotein E receptor 2 (ApoER2; also known as LDLR-related protein 8), a member of the LDLR family that interacts with dimerized b 2 GPI ( Figure 3A ). ApoER2 expressed in human and mouse trophoblasts serves as a target for anti-b 2 GPI-b 2 GPI complexes, and when cross-linked leads to reduced promigratory IL-6 and STAT-3 activity (26, 31) . Complementing these observations, in vivo studies also demonstrated a role for ApoER2 in aPLmediated fetal loss and IUGR (31) .
Effect of aPL on the production of dangerous extracellular vesicles from the syncytiotrophoblast. A common feature of aPL-affected placentae is increased syncytial knots (10) . These are aggregations of nuclei in the syncytiotrophoblast that some investigators believe are markers of aged/damaged portions of the syncytiotrophoblast that will be shed from the placenta as large extracellular vesicles called syncytial nuclear aggregates (SNAs) (32) . Antiphospholipid antibodies, internalized by the syncytiotrophoblast, disrupt mitochondria, triggering aberrant cell death that leads to the shedding of dangerous SNAs that activate the maternal vasculature (33) . Exosomes (small extracellular vesicles) released by aPL-exposed extravillous trophoblasts contain elevated levels of the TLR-8 activator, miR146a-3p (30) . Furthermore, uptake of trophoblast-derived vesicles by endothelial cells changes the transcriptome and proteome of the maternal vasculature (34) .
Effect of aPL on syncytiotrophoblast function. The syncytiotrophoblast produces human chorionic gonadotropin (HCG). Antiphospholipid antibodies reduce the growth of the syncytiotrophoblast in vitro, resulting in decreased production of HCG (35) . The ability of aPL to prevent the formation of new syncytiotrophoblasts and increase cell death suggests a reduction in overall function of the syncytiotrophoblast, leading to reduced transplacental transport, a concept supported by decreased levels of the cholesterol transporter ATP-binding cassette subfamily A1 in the placentae of patients with APS (36) .
Inflammation at the maternal-fetal interface and maternal vasculature
Mouse models have been instrumental in defining pathogenic mechanisms of aPL-mediated pregnancy complications. Passive transfer of IgG from APS patients with high titers of aPL or monoclonal human aPL into pregnant mice results in fetal resorption and growth restriction, recapitulating obstetric APS (37) . Using this model, we determined that aPL localize to placentae and that inflammation, particularly complement activation and recruitment and stimulation of neutrophils, is an essential and causative factor in placental insufficiency, fetal loss, and IUGR (31, 38) . Activation of complement stimulates infiltrating leukocytes to release TNF and soluble Flt-1, both of which are associated with impaired placentation and the development of preeclampsia (39) (40) (41) .
Neutrophils. Antibodies specific for b 2 GPI recognize b 2 GPI bound to the cell surface of neutrophils and stimulate neutrophil extracellular trap (NET) formation through reactive oxygen species-and TLR-4-dependent mechanisms (42) . Similar to patients with SLE, patients with APS show enhanced NET formation, impaired NET clearance, and higher numbers of circulating low-density granulocytes that have an increased capacity to produce cytokines and type I IFNs (42) . Increased numbers of NETs were observed infiltrating placental intervillous spaces, in association with inflammatory and vascular changes, in SLE patients with preeclampsia (43) .
Mouse models confirm a critical role for neutrophils in abnormal placental and fetal development. In pregnant mice treated with aPL, neutrophil infiltration in the placenta is observed, and deleterious effects of aPL on fetal survival and growth are abolished by neutrophil depletion ( Figure 3C ) (38) . Similarly, in antibody-independent mouse models of preeclampsia, neutrophils infiltrate the placenta, and their depletion improves placental morphology, recovers spiral artery remodeling, and rescues pregnancies (41) . In both aPLdependent and aPL-independent models, recruitment of neutrophils is triggered by complement activation at the maternal-fetal interface and leads to an increase in local TNF levels, a decrease in VEGF levels, and ultimately, abnormal placentation and fetal death ( Figure 3C) .
Complement activation. Mice deficient in alternative and classical pathway complement components and mice treated with various inhibitors of complement activation are resistant to fetal injury induced by aPL (37, 38) , indicating that both pathways contribute to damage ( Figure 3C) . Indeed, the effectiveness of heparin, usually administered at subanticoagulant doses, may be attributable, in part, to its capacity to inhibit complement activation. In aPL-treated mice, anticoagulation with hirudin or fondaparinux was not sufficient to prevent pregnancy complications (44) . The notion that complement-mediated injury is a common pathogenic mechanism that drives abnormal placental development is underscored by studies in antibody-independent mouse models of preeclampsia as well as mouse models of miscarriage, which show that blockade of complement activation rescues pregnancies (40, 41) .
Studies in women support the role of complement in pregnancy complications in patients with APS and in non-autoimmune patients. Complement fragment C4d, a marker of classical pathway activation, is present in the placentae of patients with SLE and/or APS and women with preeclampsia (10, 45, 46) . Inherited hypofunctional variants of complement regulators provide an increased risk of preeclampsia in women with SLE and/or aPL (47) . Finally, 2 studies have shown mild hypocomplementemia in patients with primary APS (48, 49) .
TNF and other inflammatory mediators downstream of complement activation. TNF is a mediator that links complement C5a-C5aR interactions and pathogenic aPL to fetal damage ( Figure 3C ). Antiphospholipid antibodies specifically targeted to decidual tissue cause a rapid increase in decidual and systemic TNF levels. C5-deficient mice show no increase in TNF and are protected against fetal death, thus identifying TNF as a critical mediator downstream of C5 activation (39) . The notion that TNF itself is pathogenic is suggested by studies showing that miscarriage induced by aPL is less frequent in mice deficient in TNF or treated with TNF blockade (39) . Furthermore, in antibodyindependent models of preeclampsia, complement activation at the maternal-fetal interface leads to increased TNF levels, reduced VEGF levels, abnormal placentation, and fetal death (41) . Blockade of complement activation or blockade of TNF improves spiral artery remodeling and rescues pregnancies (41) . Evidence that TNF contributes to the pathogenesis of adverse pregnancy outcomes in humans includes increased TNF levels in the maternal blood and amniotic fluid of patients with preeclampsia (50, 51) and elevated TNF levels at the fetal-maternal interface (52) .
C5a also triggers fetal damage through induction of tissue factor (Figure 3 ). Antiphospholipid antibodies increase tissue factor in neutrophils, which enhances oxidative burst and thus provides a mechanism for trophoblast injury and pregnancy loss (53) . Finally, complement activation products, particularly C5a, may cause an imbalance in the angiogenic factors required for normal pregnancy by triggering release of antiangiogenic factors (soluble Flt-1) (40) .
Interferon (IFN) and maternal vascular vulnerability. IFNa is a potent antiangiogenic and vasculopathic factor that causes down-regulation of proangiogenic molecules and depletion of hematopoietic progenitor cells involved in vascular remodeling, both of which lead to impaired vasculogenesis (54, 55) . IFNa plays a central role in the pathogenesis of SLE (56) . Patients with SLE in whom preeclampsia is likely to develop are more likely to have increased circulating IFNa levels before the onset of clinical symptoms compared to normotensive women, whereas in nonautoimmune patients, preeclampsia is not associated with elevated levels of IFNa (57) . In vitro and in vivo studies suggest that elevated IFNa levels contribute to the pathogenesis of preeclampsia by sensitizing maternal endothelium to the antiangiogenic effects of soluble Flt-1 and by inhibiting transcription of proangiogenic VEGF, necessary for homeostasis in some vascular beds. Endothelial cell-trophoblast interactions are impaired in the presence of elevated levels of IFNa, a potential basis for inadequate spiral artery remodeling, and the resultant placental and angiogenic dysfunction of preeclampsia. Elevated IFNa levels may identify lupus patients who are at increased risk of placenta-mediated pregnancy complications. Indeed, the increased frequency of preeclampsia in patients who have active SLE early in pregnancy, particularly those with active nephritis (58, 59) , may be related to the vasculopathic effects of elevated IFNa in many such patients.
Prediction of adverse pregnancy outcomes in APS and SLE
Biomarkers that are altered early in pregnancy are needed to identify, counsel, and manage APS patients who are at high risk of adverse pregnancy outcomes. The Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus (PROMISSE) study is the largest multicenter, multiethnic, and multiracial study to prospectively assess clinical and laboratory predictors of adverse pregnancy outcomes in women with SLE and/or APS with inactive or mild/moderate activity at conception. Using data and samples from PROMISSE, we evaluated molecules related to pathways of aPL-induced injury as biomarkers for placental insufficiency and poor pregnancy outcomes.
Antiangiogenic factors. In the maternal circulation, excess soluble Flt-1 produces a deficiency of the angiogenic factors required for vascular homeostasis. Prospective studies in otherwise healthy women demonstrate angiogenic dysregulation up to 5 weeks before clinical manifestations of preeclampsia (19) . An imbalance between circulating levels of antiangiogenic and proangiogenic proteins is also associated with IUGR and fetal death (60) in nonautoimmune patients. By 12-15 weeks of gestation, soluble Flt-1, placental growth factor, and soluble endoglin levels were markedly altered in patients with SLE and/or aPL who later developed severe adverse pregnancy outcomes, e.g., early preeclampsia, fetal/neonatal death, or indicated preterm delivery before 30 weeks of gestation (61) . At 16-19 weeks, patients with SLE and/or aPL with both placental growth factor in the lowest quartile and soluble Flt-1 in the highest quartile had .30-fold increased risk of severe adverse outcomes, and if LAC or a history of high blood pressure was also present, the rate was 94%. Importantly, circulating angiogenic factors measured during early gestation have a high negative predictive value in ruling out the development of severe adverse outcomes (61) .
Complement activation. Complement activation is prevalent and may function as a source of procoagulant and inflammatory cell activation in APS patients (48) . In nonautoimmune patients, activation of the alternative pathway of complement (evidenced by increased circulating levels of the Bb fragment) is associated with preeclampsia and preterm birth (62) . In pregnant patients with SLE and/or aPL, elevated levels of complement activation fragments and smaller increases in the C3 level than those that typically occur in normal pregnancies predict adverse outcomes (63) .
Uric acid. Until recently, an elevation in serum uric acid production in patients with pregnancy complications, such as preeclampsia, was thought to be a marker of renal dysfunction. However, new evidence suggests that the placenta may contribute to the increase in circulating uric acid. In vitro studies reveal that aPL increase trophoblast uric acid production (29) . In patients with aPL and adverse pregnancy outcomes, serum uric acid levels midgestation were significantly higher than those in patients without adverse outcomes (29) . In patients with mild-to-moderate SLE, increased levels of uric acid at midgestation correlated with preterm birth (64) .
Exosomal miR-146a-3p. In patients with aPL and adverse pregnancy outcomes, circulating exosomes contained higher levels of the TLR-8 activator, miR146a-3p, compared to the levels in healthy controls. Exosomes from patients with SLE and poor pregnancy outcomes, but without aPL, also contained higher levels of miR-146a-3p compared to those in healthy controls. Thus, both APS and SLE may be associated with this TLR-8-activating miRNA during pregnancy, and the source may be the placenta (30) .
Potential targets to prevent obstetric APS Antithrombotic therapies. Despite the administration of conventional antithrombotic treatment (heparin, alone or in combination with low-dose aspirin), pregnant women with APS continue to experience adverse outcomes. Although aspirin does not alter the effects of aPL on trophoblast function in vitro, there may be some clinical benefits (63, 65) . Stable analogs of aspirin-triggered lipoxin that resolve inflammation may have potential clinical use. The aspirin-triggered lipoxin 15-epi-lipoxin A 4 in vitro reversed the inhibitory effects of aPL and sera from APS patients on trophoblast migration and trophoblastendothelial cell interactions (28) .
The use of heparin stemmed from the notion that obstetric APS is a prothrombotic disorder, but heparin certainly influences other pathways related to pregnancy (25, 44) . Clinical and experimental studies have shown contradictory results regarding the effectiveness of low molecular weight heparin (LMWH) in preventing aPLassociated adverse pregnancy outcomes and in being able to reverse the detrimental effects of aPL on trophoblast function in vitro (66, 67) . Moreover, heparin promotes placental release of antiangiogenic soluble Flt-1 (27, 68) . Even when LMWH is administered early in pregnancy, the incidence of late gestation complications, such as preeclampsia, placental insufficiency, and IUGR, remains high. A recent meta-analysis of trials using LMWH to prevent recurrent placentamediated pregnancy complications demonstrated no benefit (69) .
Inhibition of aPL binding. Antiphospholipid antibodies can react with epitopes in all 5 domains of b 2 GPI, although there is particular interest in antibodies directed against domains I and V. The immunodominant domain of b 2 GPI is domain I (DI). Binding of b 2 GPI to human trophoblasts and endothelium is through the phospholipid-binding site in domain V. According to the current viewpoint, b 2 GPI binds to exposed anionic phospholipids (or to other receptors) on the cell surface and undergoes a conformational change that permits binding of the antibodies to a cryptic epitope, resulting in dimerization of the antigen and stabilization of the complex. Alternatively, adhesion of b 2 GPI to the cell surface may increase the antigen density, thereby favoring binding of low-avidity aPL.
Blockade of b 2 GPI binding to trophoblasts and blockade of anti-b 2 GPI binding to b 2 GPI are theoretical targets to prevent adverse pregnancy outcomes (see Table  2 ). A synthetic peptide, TIFI, shares a sequence similar to the b 2 GPI phospholipid-binding site and displaces b 2 GPI from the cell surfaces, thus inhibiting aPL binding. Repeated infusions of TIFI in pregnant mice protected them against complications induced by administration of human aPL (70) . Recombinant DI peptides or recombinant mutant DI with enhanced aPL-binding properties blocks aPL binding and inhibits aPL-induced pathogenicity (71) . Similarly, a monoclonal antibody (1N11) blocks the interaction of b 2 GPI with ApoER2, thereby attenuating aPL-related pregnancy complications in mice (72) . Finally, a non-complement-activating monoclonal aPL reactive with DI (MBB2DCH2) competes with antib 2 GPI antibodies from APS patients, preventing the in vitro pathogenic effects of aPL and rescuing pregnancies in mouse models of obstetric APS (73) .
Blockade of inflammation mediators. Given the apparent role of placental miR-146a-3p-mediated TLR-8 activation and uric acid-driven inflammasome activation in the placenta in response to aPL (29, 30) , inhibition of these pathways may be beneficial (Table 2) . Chloroquine is a TLR-7/TLR-8 inhibitor and is used safely during pregnancy, even in the first trimester, primarily as an antimalarial treatment (74, 75) . Hydroxychloroquine is used clinically to treat patients with lupus and those with APS and to attempt to prevent congenital heart block in at-risk pregnancies (75) . Chloroquine has been shown to inhibit the internalization of aPL into the syncytiotrophoblast and consequent production of dangerous SNAs (23) . Hydroxychloroquine has also been shown to reverse the effects of aPL on annexin A5 and coagulation on the surface of trophoblasts, and it prevents the effects of aPL on trophoblast migration, HCG secretion, and fusion (35, 76, 77) .
Allopurinol is a xanthine oxidase inhibitor and prevents NLRP3 inflammasome activation by inhibiting production of uric acid (78) . Studies in placenta have focused on the ability of allopurinol to reduce oxidative stress (79); however, its ability to reduce inflammation in pregnancy has not been addressed. Allopurinol is also safe to use during pregnancy and by crossing the placenta may also provide neuroprotection for the developing fetus by preventing oxidative stress (80) . Because placental inflammation has been linked to prenatal brain injury, and IL-1b is a key mediator (81), preventing placental inflammasome activity may not only protect against adverse pregnancy outcomes but also provide protection against inflammation-induced fetal injury.
Statins have pleotropic antiinflammatory and antithrombotic effects. Although pravastatin did not prevent aPL-mediated changes in human first-trimester trophoblast function in vitro (82) , statins have been shown to decrease the levels of biomarkers of inflammation in APS, reverse markers of angiogenic dysregulation, and, as an adjunct to heparin and low-dose aspirin, may attenuate aPL-associated complications in pregnant patients (83, 84) .
Current strategies to block complement-mediated injury include inhibition of C5 cleavage, blockade of C5a-C5a receptor interactions, and prevention of alternative pathway activation with monoclonal antibodies or small molecules (Table 2) . Eculizumab, a monoclonal antibody that prevents C5 cleavage, has been used in pregnant women with paroxysmal nocturnal hemoglobinuria and patients with catastrophic APS (85) . It has also been suggested that hydroxychloroquine prevents placental abnormalities by inhibiting complement (86) .
TNF is a critical effector of abnormal placental development and fetal damage in mouse models, and TNF blockade restores angiogenic balance and spiral artery remodeling and rescues pregnancies (39, 41) . There is evidence that TNF contributes to the pathogenesis of adverse outcomes in humans (50) (51) (52) . Importantly, anti-TNF agents are available and have proven safe in pregnancy (87) . The Improve Pregnancy in APS with Certolizumab Therapy (IMPACT) trial is a recently initiated, open-label single-stage phase II trial to evaluate the effect of certolizumab, a TNF inhibitor that does not cross the placenta and has been shown to be well tolerated in pregnancy, on reducing the risk of adverse pregnancy outcomes in high-risk pregnancies in women with APS (Table 2) .
Conclusions
Antiphospholipid antibodies have emerged as triggers of innate immune inflammatory pathways within trophoblasts and at the maternal-fetal interface. No longer simply prothrombotic autoantibodies that activate endothelial cells and platelets, aPL have been shown to bind trophoblasts and disrupt their normal function. Localized to trophoblasts via b 2 GPI, aPL activate membrane receptors and intracellular danger sensors to initiate inflammation (similar to other autoantibodies), but in the case of aPL, the target is the developing placenta, with adverse consequences for the fetus and mother. Elucidation of these injurious pathways has revealed several potential approaches that use therapies that are currently available or that are being developed to prevent the inflammation and trophoblast dysfunction that lead to adverse pregnancy outcomes. These new therapeutic options are emerging as a result of increased understanding of the mechanisms by which aPL cause disease, highlighting the need for high-quality mechanistic investigations. As we discover more about disease pathogenesis, we will become better at predicting and preventing obstetric APS.
